Despite safety issues, Vioxx still in demand

For every regulatory action, it seems that there must be a backlash. This time, it's a move by consumers to bring back the controversial drug, Vioxx. Patients who once depended on the drug for arthritis relief are still lobbying Merck to get the drug back on the market--despite the documented risk of heart attacks, strokes, even death. Consumer advocates say it might be a case of rose-colored hindsight; patients convinced only Vioxx can help them may simply have exaggerated memories of the drug's effects.

To learn more about this story:
 - read this piece from FiercePharma

Related Articles:
Vioxx defense dealt a blow by new study results. Report
Up to 100,000 Vioxx claims expected. Report
Merck faces long road in Vioxx battle. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.